Thursday, September 28, 2023 2:52:00 PM
An example of how devastating a diagnosis of AD can be was illustrated by a recent case of fraudulent diagnosis of AD in TOLEDO, Ohio
-- QUOTE..."A former director of an Ohio memory-loss clinic accused by dozens of patients of falsely diagnosing them with Alzheimer’s disease has been sentenced on federal fraud charges, along with her physician husband.
Sherry-Ann Jenkins received nearly six years in prison on Tuesday, while Oliver Jenkins(MD) got a 41-month sentence. The couple was convicted in March on conspiracy, mail fraud, wire fraud and health-care fraud charges after being indicted in May 2020.
The U.S. Justice Department has said Sherry-Ann Jenkins was not trained or licensed to provide any medical care but presented herself as a doctor and billed patients for unneeded treatments....The patients said they spent months undergoing treatment while planning out their final years, thinking they would die soon. Some quit their jobs or took one last special trip. One killed himself; others said they considered suicide."
If Vascepa is shown by the Brave study to provide even a modest amount of help in delaying the onset of AD or ameliorating it,(in addition to its positive effect on CVD and other diseases) the drug would be very well received by the world.
-- QUOTE..."A former director of an Ohio memory-loss clinic accused by dozens of patients of falsely diagnosing them with Alzheimer’s disease has been sentenced on federal fraud charges, along with her physician husband.
Sherry-Ann Jenkins received nearly six years in prison on Tuesday, while Oliver Jenkins(MD) got a 41-month sentence. The couple was convicted in March on conspiracy, mail fraud, wire fraud and health-care fraud charges after being indicted in May 2020.
The U.S. Justice Department has said Sherry-Ann Jenkins was not trained or licensed to provide any medical care but presented herself as a doctor and billed patients for unneeded treatments....The patients said they spent months undergoing treatment while planning out their final years, thinking they would die soon. Some quit their jobs or took one last special trip. One killed himself; others said they considered suicide."
If Vascepa is shown by the Brave study to provide even a modest amount of help in delaying the onset of AD or ameliorating it,(in addition to its positive effect on CVD and other diseases) the drug would be very well received by the world.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
